Blood cancers

Cure in CLL requires disease control plus immune restoration

Disease eradication combined with immune restoration represent the “holy grail” of treatment for CLL, according to Australian haematologists. Writing in Leukemia & Lymphoma, Dr Sasanka Handunnetti and Professor Con Tam from the Peter MacCallum Cancer Centre, said the immune impacts of Bruton tyrosine kinase (BTK) inhibitors and possibly selective BCL-2 inhibitors might help achieve that ...

Already a member?

Login to keep reading.

© 2021 the limbic